Literature DB >> 16763908

Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders.

Michael H Gelb1, Frantisek Turecek, C Ron Scott, Nestor A Chamoles.   

Abstract

Tandem mass spectrometry is currently used in newborn screening programmes to quantify the level of amino acids and acylcarnitines in dried blood spots for detection of metabolites associated with treatable diseases. We have developed assays for lysosomal enzymes in rehydrated dried blood spots in which a set of substrates is added and the set of corresponding enzymatic products are quantified using tandem mass spectrometry with the aid of mass-differentiated internal standards. We have developed a multiplex assay of the set of enzymes that, when deficient, cause the lysosomal storage disorders Fabry, Gaucher, Hurler, Krabbe, Niemann-Pick A/B and Pompe diseases. These diseases were selected because treatments are now available or expected to emerge shortly. The discovery that acarbose is a selective inhibitor of maltase glucoamylase allows the Pompe disease enzyme, acid alpha-glucosidase, to be selectively assayed in white blood cells and dried blood spots. When tested with dried blood spots from 40 unaffected individuals and 10-12 individuals with the lysosomal storage disorder, the tandem mass spectrometry assay led to the correct identification of the affected individuals with 100% sensitivity. Many of the reagents needed for the new assays are commercially available, and those that are not are being prepared under Good Manufacturing Procedures for approval by the FDA. Our newborn screening assay for Krabbe disease is currently being put in place at the Wadsworth Center in New York State for the analysis of approximately 1000 dried blood spots per day. Summary We have developed tandem mass spectrometry for the direct assay of lysosomal enzymes in rehydrated dried blood spots that can be implemented for newborn screening of lysosomal storage disorders. Several enzymes can be analysed by a single method (multiplex analysis) and in a high-throughput manner appropriate for newborn screening laboratories.

Entities:  

Mesh:

Year:  2006        PMID: 16763908      PMCID: PMC2488386          DOI: 10.1007/s10545-006-0265-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

1.  Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease.

Authors:  K Umapathysivam; J J Hopwood; P J Meikle
Journal:  Clin Chem       Date:  2001-08       Impact factor: 8.327

2.  Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease.

Authors:  Yijun Li; Knut Brockmann; Frantisek Turecek; C Ronald Scott; Michael H Gelb
Journal:  Clin Chem       Date:  2004-03       Impact factor: 8.327

3.  Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.

Authors:  Maria L Escolar; Michele D Poe; James M Provenzale; Karen C Richards; June Allison; Susan Wood; David A Wenger; Daniel Pietryga; Donna Wall; Martin Champagne; Richard Morse; William Krivit; Joanne Kurtzberg
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

4.  Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry.

Authors:  Tina Rozaklis; Steven L Ramsay; Phillip D Whitfield; Enzo Ranieri; John J Hopwood; Peter J Meikle
Journal:  Clin Chem       Date:  2002-01       Impact factor: 8.327

5.  Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards.

Authors:  Néstor A Chamoles; Mariana Blanco; Daniela Gaggioli; Carina Casentini
Journal:  Clin Chim Acta       Date:  2002-04       Impact factor: 3.786

6.  Direct profiling of multiple enzyme activities in human cell lysates by affinity chromatography/electrospray ionization mass spectrometry: application to clinical enzymology.

Authors:  S A Gerber; C R Scott; F Turecek; M H Gelb
Journal:  Anal Chem       Date:  2001-04-15       Impact factor: 6.986

7.  Affinity capture and elution/electrospray ionization mass spectrometry assay of phosphomannomutase and phosphomannose isomerase for the multiplex analysis of congenital disorders of glycosylation types Ia and Ib.

Authors:  Yijun Li; Yuko Ogata; Hudson H Freeze; C Ronald Scott; Frantisek Turecek; Michael H Gelb
Journal:  Anal Chem       Date:  2003-01-01       Impact factor: 6.986

Review 8.  Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.

Authors:  J Muenzer; J C Lamsa; A Garcia; J Dacosta; J Garcia; D A Treco
Journal:  Acta Paediatr Suppl       Date:  2002

9.  Screening newborns for inborn errors of metabolism by tandem mass spectrometry.

Authors:  Bridget Wilcken; Veronica Wiley; Judith Hammond; Kevin Carpenter
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

10.  Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Authors:  Paul Harmatz; Chester B Whitley; Lewis Waber; Ray Pais; Robert Steiner; Barbara Plecko; Paige Kaplan; Julie Simon; Ellen Butensky; John J Hopwood
Journal:  J Pediatr       Date:  2004-05       Impact factor: 4.406

View more
  55 in total

1.  Newborn screening.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2010-05

2.  Direct assay of delta-aminolevulinic acid dehydratase in heme biosynthesis for the detection of porphyrias by tandem mass spectrometry.

Authors:  John R Choiniere; C Ronald Scott; Michael H Gelb; Frantisek Turecek
Journal:  Anal Chem       Date:  2010-08-01       Impact factor: 6.986

3.  Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome).

Authors:  Brian J Wolfe; Sophie Blanchard; Martin Sadilek; C Ronald Scott; Frantisek Turecek; Michael H Gelb
Journal:  Anal Chem       Date:  2010-12-30       Impact factor: 6.986

4.  Introducing new screens: why are we all doing different things?

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2007-07-06       Impact factor: 4.982

5.  Expanded newborn screening in Europe 2007.

Authors:  O A Bodamer; G F Hoffmann; M Lindner
Journal:  J Inherit Metab Dis       Date:  2007-07-23       Impact factor: 4.982

6.  Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates.

Authors:  O P van Diggelen; L F Oemardien; N A M E van der Beek; M A Kroos; H K Wind; Y V Voznyi; D Burke; M Jackson; B G Winchester; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2009-04-19       Impact factor: 4.982

Review 7.  Newborn blood spot screening: new opportunities, old problems.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2009-05-04       Impact factor: 4.982

8.  In response to 'Newborn screening in North America' (Therrell and Adams (2007) J Inherit Metab Dis 30:447-465).

Authors:  H Vallance; S Sirrs; F Bamforth; S Stockler-Ipsiroglu
Journal:  J Inherit Metab Dis       Date:  2008-10-16       Impact factor: 4.982

9.  Protonation sites and dissociation mechanisms of t-butylcarbamates in tandem mass spectrometric assays for newborn screening.

Authors:  Zdeněk Spáčil; Renjie Hui; Michael H Gelb; František Tureček
Journal:  J Mass Spectrom       Date:  2011-10       Impact factor: 1.982

10.  Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis.

Authors:  Braden Fitterer; Patricia Hall; Nick Antonishyn; Rajagopal Desikan; Michael Gelb; Denis Lehotay
Journal:  Mol Genet Metab       Date:  2014-01-13       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.